Cancer therapy: An evolved approach

Nature

Volumn 532, Issue 7598, 2016, Pages 166-168

  Willyard, Cassandra ^a  

^a NONE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CRIZOTINIB; OSIMERTINIB; ANTINEOPLASTIC AGENT;

CANCER CELL; CANCER CHEMOTHERAPY; CANCER IMMUNOLOGY; CANCER THERAPY; COST BENEFIT ANALYSIS; GENE MUTATION; HUMAN; METASTASIS; NEOPLASM; NONHUMAN; NOTE; PRIORITY JOURNAL; TUMOR GROWTH; ADOPTIVE IMMUNOTHERAPY; ANIMAL; CHEMICALLY INDUCED; CLINICAL TRIAL (TOPIC); DNA MUTATIONAL ANALYSIS; DOSE RESPONSE; DRUG EFFECTS; DRUG RESISTANCE; ECONOMICS; FEMALE; GENETIC SELECTION; GENETICS; MOLECULAR EVOLUTION; MOLECULARLY TARGETED THERAPY; MOUSE; MUTATION; NEOPLASM METASTASIS; NEOPLASMS; PATHOLOGY; PREVENTION AND CONTROL; PROCEDURES; TRENDS; TUMOR MICROENVIRONMENT; TUMOR RECURRENCE;

ANIMALS; ANTINEOPLASTIC AGENTS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CLINICAL TRIALS AS TOPIC; DNA MUTATIONAL ANALYSIS; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG RESISTANCE, NEOPLASM; EVOLUTION, MOLECULAR; FEMALE; HUMANS; IMMUNOTHERAPY, ADOPTIVE; MICE; MOLECULAR TARGETED THERAPY; MUTATION; NEOPLASM METASTASIS; NEOPLASM RECURRENCE, LOCAL; NEOPLASMS; SELECTION, GENETIC; TUMOR MICROENVIRONMENT;

EID: 84964499425     PISSN: 00280836     EISSN: 14764687     Source Type: Journal    
DOI: 10.1038/532166a     Document Type: Note

References (9)

1. Misale, S. et al. Nature Commun. 6, 8305 (2015).
2. Gerlinger, M. et al. N. Engl. J. Med. 366, 883-892 (2012).
3. Bozic, I. et al. eLife 2, e00747 (2013).
4. McGranahan, N. et al. Science 351, 1463-1469 (2016).
5. Turke, A. B. et al. Cancer Cell 17, 77-88 (2010).
6. Bhang, H. C. et al. Nature Med. 21, 440-448 (2015).
7. Su, K. Y. et al. J. Clin. Oncol. 30, 433-440 (2012).
8. Enriquez-Navas, P. M. et al. Sci. Transl. Med. 8, 327ra24 (2016).
9. Shaw, A. T. et al. N. Engl. J. Med. 374, 54-61 (2016).